Lawrence, Stacy
Lahteenmaki, Riku
Article History
First Online: 8 July 2014
Change Date: 3 September 2014
Change Type: Erratum
Change Date: 25 June 2015
Change Type: Erratum
Change Details: In the version of this article initially published, in Table 8, Enbrel (etanercept) was left off the table. It should have been in the number 2 spot in the table with 2013 revenue at $8,739 million. In addition, the units of the last column, which are in $ millions, were omitted in the title. The errors have been corrected in the HTML and PDF versions of the article.
Change Details: In the version of the article initially published, some companies that went public in 2013 were missing from the table of 2013 IPOs (Table 4). Thirteen companies have been added to the table, including Celyad (formerly Cardio3 Biosciences), Erytech, Immunicum, Innate Immune Therapeutics, Kadimastem, Karyopharm Therapeutics, Kindred, Macrogenics, Oncolys Biopharma, Reprocell, Tetralogic, Veracyte and Xencor; in the figure of global IPOs (Fig. 2), the number of IPOs in 2013 and the average dollar amount raised have been corrected to reflect the additional companies.